Press release
Gallbladder Cancer Clinical Trials Analysis 2025 Innovative Combinations and Immunotherapy Strategies Reshape the Treatment Landscape | DelveInsight
Checkpoint inhibitors, including PD-1 and PD-L1 antibodies, are being investigated alone and in combination with chemotherapy to extend overall survival in advanced cases. Parallel trials are assessing FGFR2, HER2, and IDH pathway inhibitors, offering precision-based approaches for biomarker-driven subsets of gallbladder cancer.
Innovative modalities such as antibody-drug conjugates and tumor vaccines are also advancing, with early results indicating potential for durable responses. Global collaborations are enabling adaptive trial designs and accelerated recruitment, particularly in high-prevalence regions such as South Asia and Latin America.
With several late-stage trials maturing in 2025, the gallbladder cancer treatment landscape is poised for transformation, driven by immuno-oncology and precision medicine strategies that aim to improve outcomes in this hard-to-treat cancer significantly
Explore the full pipeline analysis for gallbladder cancer and uncover key opportunities @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Gallbladder Cancer Pipeline Report
• DelveInsight's Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline drugs for Gallbladder Cancer treatment.
• The leading Gallbladder Cancer companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others are evaluating their lead assets to improve the Gallbladder Cancer treatment landscape.
• Key Gallbladder Cancer pipeline therapies in various stages of development include Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
• In December 2024, Checkpoint Therapeutics, Inc. announced that the FDA approved UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
• In December 2024, the FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum- and fluoropyrimidine-based chemotherapy for first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1.
• In December 2024, Jazz Pharmaceuticals announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for intravenous use was recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines as a category 2A treatment option for Biliary Tract Cancers (BTC).
• In December 2014, Ipsen Biopharmaceuticals announced that the FDA approved SOMATULINE DEPOT for the treatment of GEP-Neuroendocrine Tumors in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).
• In April 2024, Perspective Therapeutics announced the selection of investigational product [212Pb]VMT-a-NET for the treatment of certain patients with neuroendocrine tumors by the FDA to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.
Request a sample and discover the recent breakthroughs happening in the Gallbladder Cancer pipeline landscape @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Overview
Gallbladder cancer is a rare cancer that begins in the gallbladder, a small organ located under the liver responsible for storing bile, which aids in digestion. Most cases are adenocarcinomas, originating from glandular cells lining the gallbladder. It typically develops due to DNA mutations that cause abnormal, uncontrolled cell growth. Gallbladder cancer is more common in middle-aged women, particularly those with a history of gallstones, but it can also affect men. The cancer may present as various types, including papillary adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma. Due to its rarity and the often lack of symptoms in the early stages, it is frequently diagnosed at an advanced stage, making early detection vital for better treatment outcomes.
Find out more about Gallbladder Cancer medication @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Treatment Analysis: Drug Profile
Durvalumab: Celgene
Durvalumab, developed by Celgene, is a human immunoglobulin G1 kappa monoclonal antibody currently under development for the treatment of gallbladder cancer. It works by inhibiting the immune response through blocking the interaction of PD-L1 with PD-1 and CD80. In Phase I clinical trials, the drug has shown promising efficacy and a favorable safety profile.
ONC 201: Ohara Pharmaceuticals
ONC 201, a novel drug candidate from Ohara Pharmaceuticals, is an orally administered small molecule being developed for the treatment of gallbladder cancer. It functions by inactivating the Akt/ERK signaling pathway, which leads to the upregulation of the proapoptotic immune cytokine TRAIL, promoting cancer cell death.
Learn more about the novel and emerging Gallbladder Cancer pipeline therapies @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Gallbladder Cancer Pipeline Report
• Coverage: Global
• Key Gallbladder Cancer Companies: Celgene, MedImmune, Ohara Pharmaceuticals, and others.
• Key Gallbladder Cancer Pipeline Therapies: Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
Dive deep into rich insights for drugs used for Gallbladder Cancer treatment; visit @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Gallbladder Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Gallbladder Cancer Pipeline Therapeutics
6. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
7. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
8. Gallbladder Cancer Pipeline: Mid-Stage Products (Phase II)
9. Gallbladder Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gallbladder Cancer Clinical Trials Analysis 2025 Innovative Combinations and Immunotherapy Strategies Reshape the Treatment Landscape | DelveInsight here
News-ID: 4202312 • Views: …
More Releases from DelveInsight Business
T-Cell Lymphoma Pipeline Grows as 90+ Pharma Companies Advance Novel Therapies, …
DelveInsight's "T-Cell Lymphoma - Pipeline Insight, 2026" report provides comprehensive insights about 90+ companies developing several pipeline drugs in the T-Cell Lymphoma pipeline landscape. It covers the T-cell lymphoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the T-Cell Lymphoma treatment landscape.…
Prostate Cancer Pipeline to Witness Massive Growth as 140+ Pharma Companies Adva …
DelveInsight's "Prostate Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 140+ companies developing several pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Prostate Cancer treatment landscape.…
Refractory Multiple Myeloma Pipeline Expands as 75+ Pharma Companies Advance 80+ …
DelveInsight's "Refractory Multiple Myeloma – Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Refractory…
Pulmonary Fibrosis Pipeline Progresses as 110+ Pharma Companies Advance 140+ Nov …
DelveInsight's "Pulmonary Fibrosis - Pipeline Insight, 2026" report provides comprehensive insights about 110+ companies developing over 140 pipeline drugs in the Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Pulmonary Fibrosis treatment…
More Releases for Gallbladder
When Upper Abdominal Pain May Signal Gallbladder Disease
Healthy Life Bariatrics offers laparoscopic gallbladder surgery in Los Angeles for patients with painful or complicated gallstones. Dr. Babak Moein evaluates symptoms and diagnostic imaging to determine whether minimally invasive cholecystectomy is appropriate, helping patients achieve lasting relief with smaller incisions and a relatively rapid recovery.
Healthy Life Bariatrics is highlighting laparoscopic gallbladder surgery as an effective treatment option for patients experiencing painful gallstones and other forms of symptomatic gallbladder disease.
Gallstones…
Gallbladder Cancer Epidemiology Forecast Insights
The Gallbladder Cancer Epidemiology Forecast has become an essential resource in modern healthcare, guiding clinicians, researchers, and policymakers as they work to understand a disease that often presents late and progresses rapidly. This type of forecast does not focus on financial figures or market performance; instead, it maps out the current and future landscape of gallbladder cancer occurrence, patterns, influential factors, and evolving patient needs. As gallbladder cancer remains one…
Gallbladder Surgery Under Dr. Moein in Los Angeles
Gallbladder surgery has become a preferred option for many in Los Angeles seeking relief from painful gallstones and cholecystitis. At Healthy Life Bariatrics, board-certified surgeon Dr. Babak Moein performs minimally invasive laparoscopic gallbladder removal, offering patients faster recovery, smaller incisions, and fewer complications.
More and more patients in Los Angeles are turning to minimally invasive gallbladder surgery to treat painful symptoms of gallstones and cholecystitis. Surgeons in the area, including trusted…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Cancer Treatment Market Expands With Emergence of Novel Chemotherape …
Gallbladder Cancer Treatment Market Overview
The Gallbladder Cancer Treatment Market is projected to grow from USD 720 Million in 2025 to USD 1.4 Billion by 2032, at a CAGR of 10.1% during the forecast period.
Coherent Market Insights is pleased to release its latest Gallbladder Cancer Treatment Market research report, offering an in-depth analysis of the U.S. Gallbladder Cancer Treatment Market Landscape from 2025 to 2032. This report delivers reliable projections across…
Gallbladder Cancer Market to Rise by 2032 | Celgene, MedImmune, Ohara Pharmaceut …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
